Shots:
- GSK has entered into an agreement to acquire 35Pharma, incl. its asset HS235, expanding scalable growth opportunities within its Respiratory, Immunology & Inflammation portfolio
- As per the deal, GSK will acquire 100% of 35Pharma’s equity for $950M in cash, payable at closing
- HS235, a therapy targeting the activin receptor signalling pathway, has completed P-I trials in healthy volunteers, with clinical trials set to begin in pulmonary arterial hypertension & pulmonary hypertension due to heart failure with preserved ejection fraction
Ref: GSK | Image: 35Pharma | Press Release
Related News: Frontier Biotechnologies and GSK Forge ~$1B Global Licensing Deal for siRNA Therapeutics
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
